DOCSLIB.ORG

Med Id# Medication Name Dea Class Code Controlled

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MED ID# MEDICATION NAME DEA CLASS CODE CONTROLLED? 103203 ABSTRAL 100 MCG SUBLINGUAL SUBL C-II High abuse potential Yes 103268 ABSTRAL 200 MCG SUBLINGUAL SUBL C-II High abuse potential Yes 103269 ABSTRAL 300 MCG SUBLINGUAL SUBL C-II High abuse potential Yes 103270 ABSTRAL 400 MCG SUBLINGUAL SUBL C-II High abuse potential Yes 103271 ABSTRAL 600 MCG SUBLINGUAL SUBL C-II High abuse potential Yes 103272 ABSTRAL 800 MCG SUBLINGUAL SUBL C-II High abuse potential Yes 28034 ACETAMINOPHEN-CAFF-BUTALBITAL 325-40-50 MG/15 ML ORAL ELIX C-III Moderate dependence Yes 15248 ACETAMINOPHEN-CAFF-BUTALBITAL 500-40-50 MG ORAL TAB C-III Moderate dependence Yes 112694 ACETAMINOPHEN-CODEINE 120 MG-12 MG /5 ML (5 ML) ORAL SOLN C-V Limited abuse potential Yes 8540 ACETAMINOPHEN-CODEINE 120-12 MG/5 ML ORAL ELIX C-V Limited abuse potential Yes 3535 ACETAMINOPHEN-CODEINE 120-12 MG/5 ML ORAL SOLN C-V Limited abuse potential Yes 7477 ACETAMINOPHEN-CODEINE 120-12 MG/5 ML ORAL SUSP C-V Limited abuse potential Yes 113930 ACETAMINOPHEN-CODEINE 240 MG-24 MG /10 ML (10 ML) ORAL SOLN C-V Limited abuse potential Yes 113931 ACETAMINOPHEN-CODEINE 300 MG-30 MG /12.5 ML ORAL SOLN C-V Limited abuse potential Yes 6746 ACETAMINOPHEN-CODEINE 300-15 MG ORAL TAB C-III Moderate dependence Yes 7002 ACETAMINOPHEN-CODEINE 300-30 MG ORAL TAB C-III Moderate dependence Yes 16078 ACETAMINOPHEN-CODEINE 300-60 MG ORAL TAB C-III Moderate dependence Yes 113932 ACETAMINOPHEN-CODEINE 360 MG-36 MG /15 ML (15 ML) ORAL SOLN C-V Limited abuse potential Yes 37709 ACETAMINOPHEN-CODEINE 650-30 MG ORAL TAB C-III Moderate dependence Yes 94732 ACETAMINOPHEN-CODEINE 650-60 MG ORAL TAB C-III Moderate dependence Yes 15302 ACETAMINOPHN-ISOMETH-DICHLORAL 325-65-100 MG ORAL CAP C-IV Limited Dependence Yes 8666 ACTIQ 1,200 MCG BUCL LPOP C-II High abuse potential Yes 11993 ACTIQ 1,600 MCG BUCL LPOP C-II High abuse potential Yes 12923 ACTIQ 200 MCG BUCL LPOP C-II High abuse potential Yes 3055 ACTIQ 400 MCG BUCL LPOP C-II High abuse potential Yes 10942 ACTIQ 600 MCG BUCL LPOP C-II High abuse potential Yes 3360 ACTIQ 800 MCG BUCL LPOP C-II High abuse potential Yes 20320 ADDERALL 10 MG ORAL TAB C-II High abuse potential Yes 16108 ADDERALL 12.5 MG ORAL TAB C-II High abuse potential Yes 2525 ADDERALL 15 MG ORAL TAB C-II High abuse potential Yes 1270 ADDERALL 20 MG ORAL TAB C-II High abuse potential Yes 1075 ADDERALL 30 MG ORAL TAB C-II High abuse potential Yes 4392 ADDERALL 5 MG ORAL TAB C-II High abuse potential Yes 17890 ADDERALL 7.5 MG ORAL TAB C-II High abuse potential Yes 15134 ADDERALL XR 10 MG ORAL CP24 C-II High abuse potential Yes 23962 ADDERALL XR 15 MG ORAL CP24 C-II High abuse potential Yes 8299 ADDERALL XR 20 MG ORAL CP24 C-II High abuse potential Yes 23963 ADDERALL XR 25 MG ORAL CP24 C-II High abuse potential Yes 9717 ADDERALL XR 30 MG ORAL CP24 C-II High abuse potential Yes 23961 ADDERALL XR 5 MG ORAL CP24 C-II High abuse potential Yes 15029 ADIPEX-P 37.5 MG ORAL CAP C-IV Limited Dependence Yes 4353 ADIPEX-P 37.5 MG ORAL TAB C-IV Limited Dependence Yes 61025 ALA-HIST AC 7.5-10 MG/5 ML ORAL LIQD C-V Limited abuse potential Yes 60808 ALA-HIST DHC 7.5-3 MG/5 ML ORAL LIQD C-V Limited abuse potential Yes 89047 ALAGESIC LQ 50-325-40 MG/15 ML ORAL SOLN C-III Moderate dependence Yes 17072 ALFENTA 500 MCG/ML INJ SOLN C-II High abuse potential Yes 9067 ALFENTANIL 500 MCG/ML INJ SOLN C-II High abuse potential Yes 53381 ALLFEN CD 10-400 MG ORAL TAB C-III Moderate dependence Yes 92497 ALLFEN CDX 20-200 MG/5 ML ORAL LIQD C-III Moderate dependence Yes 60649 ALLFEN CDX 20-400 MG ORAL TAB C-III Moderate dependence Yes 10000 ALPRAZOLAM 0.25 MG ORAL TAB C-IV Limited Dependence Yes 37992 ALPRAZOLAM 0.25 MG ORAL TBDL C-IV Limited Dependence Yes 9691 ALPRAZOLAM 0.5 MG ORAL TAB C-IV Limited Dependence Yes 28239 ALPRAZOLAM 0.5 MG ORAL TB24 C-IV Limited Dependence Yes 37993 ALPRAZOLAM 0.5 MG ORAL TBDL C-IV Limited Dependence Yes 3318 ALPRAZOLAM 1 MG ORAL TAB C-IV Limited Dependence Yes 28238 ALPRAZOLAM 1 MG ORAL TB24 C-IV Limited Dependence Yes 37994 ALPRAZOLAM 1 MG ORAL TBDL C-IV Limited Dependence Yes 20388 ALPRAZOLAM 1 MG/ML ORAL CONC C-IV Limited Dependence Yes 16651 ALPRAZOLAM 2 MG ORAL TAB C-IV Limited Dependence Yes 28237 ALPRAZOLAM 2 MG ORAL TB24 C-IV Limited Dependence Yes 37995 ALPRAZOLAM 2 MG ORAL TBDL C-IV Limited Dependence Yes 28236 ALPRAZOLAM 3 MG ORAL TB24 C-IV Limited Dependence Yes 16715 ALPRAZOLAM INTENSOL 1 MG/ML ORAL CONC C-IV Limited Dependence Yes 4213 ALPRAZOLAM MISC POWD C-IV Limited Dependence Yes 44866 ALPRAZOLAM-DIETARY SUPP NO.17 0.25 MG ORAL CMPK C-IV Limited Dependence Yes 19359 AMBIEN 10 MG ORAL TAB C-IV Limited Dependence Yes 19171 AMBIEN 5 MG ORAL TAB C-IV Limited Dependence Yes 39229 AMBIEN CR 12.5 MG ORAL TBMP C-IV Limited Dependence Yes 39228 AMBIEN CR 6.25 MG ORAL TBMP C-IV Limited Dependence Yes 61843 AMBIFED CD 30-10-400 MG ORAL TAB C-III Moderate dependence Yes 61844 AMBIFED CDX 30-20-400 MG ORAL TAB C-III Moderate dependence Yes 61841 AMBIFED-G CD 20-10-400 MG ORAL TAB C-III Moderate dependence Yes 61842 AMBIFED-G CDX 20-20-400 MG ORAL TAB C-III Moderate dependence Yes 2128 AMITRIPTYLINE-CHLORDIAZEPOXIDE 12.5-5 MG ORAL TAB C-IV Limited Dependence Yes 10718 AMITRIPTYLINE-CHLORDIAZEPOXIDE 25-10 MG ORAL TAB C-IV Limited Dependence Yes 10027 AMOBARBITAL SODIUM 500 MG INJ SOLR C-II High abuse potential Yes 20720 AMPHETAMINE SALT COMBO 10 MG ORAL TAB C-II High abuse potential Yes 27774 AMPHETAMINE SALT COMBO 12.5 MG ORAL TAB C-II High abuse potential Yes 27775 AMPHETAMINE SALT COMBO 15 MG ORAL TAB C-II High abuse potential Yes 20721 AMPHETAMINE SALT COMBO 20 MG ORAL TAB C-II High abuse potential Yes 20722 AMPHETAMINE SALT COMBO 30 MG ORAL TAB C-II High abuse potential Yes 20719 AMPHETAMINE SALT COMBO 5 MG ORAL TAB C-II High abuse potential Yes 27773 AMPHETAMINE SALT COMBO 7.5 MG ORAL TAB C-II High abuse potential Yes 15880 AMPHETAMINE-DEXTROAMPHETAMINE 10 MG ORAL CP24 C-II High abuse potential Yes 4757 AMPHETAMINE-DEXTROAMPHETAMINE 10 MG ORAL TAB C-II High abuse potential Yes 5257 AMPHETAMINE-DEXTROAMPHETAMINE 12.5 MG ORAL TAB C-II High abuse potential Yes 23957 AMPHETAMINE-DEXTROAMPHETAMINE 15 MG ORAL CP24 C-II High abuse potential Yes 14461 AMPHETAMINE-DEXTROAMPHETAMINE 15 MG ORAL TAB C-II High abuse potential Yes 11030 AMPHETAMINE-DEXTROAMPHETAMINE 20 MG ORAL CP24 C-II High abuse potential Yes 12949 AMPHETAMINE-DEXTROAMPHETAMINE 20 MG ORAL TAB C-II High abuse potential Yes 23958 AMPHETAMINE-DEXTROAMPHETAMINE 25 MG ORAL CP24 C-II High abuse potential Yes 18124 AMPHETAMINE-DEXTROAMPHETAMINE 30 MG ORAL CP24 C-II High abuse potential Yes 9051 AMPHETAMINE-DEXTROAMPHETAMINE 30 MG ORAL TAB C-II High abuse potential Yes 23956 AMPHETAMINE-DEXTROAMPHETAMINE 5 MG ORAL CP24 C-II High abuse potential Yes 19656 AMPHETAMINE-DEXTROAMPHETAMINE 5 MG ORAL TAB C-II High abuse potential Yes 106225 AMPHETAMINE-DEXTROAMPHETAMINE 5 MG/5 ML ORAL SUSP C-II High abuse potential Yes 597 AMPHETAMINE-DEXTROAMPHETAMINE 7.5 MG ORAL TAB C-II High abuse potential Yes 1200 AMYTAL SODIUM 500 MG INJ SOLR C-II High abuse potential Yes 19149 ANADROL-50 50 MG ORAL TAB C-III Moderate dependence Yes 107114 ANDRODERM 2 MG/24 HOUR TRANSDERMAL PT24 C-III Moderate dependence Yes 3044 ANDRODERM 2.5 MG/24 HR TD PT24 C-III Moderate dependence Yes 107111 ANDRODERM 4 MG/24 HR TRANSDERMAL PT24 C-III Moderate dependence Yes 15391 ANDRODERM 5 MG/24 HR TD PT24 C-III Moderate dependence Yes 5044 ANDROGEL 1 % (25 MG) TD GLPK C-III Moderate dependence Yes 11021 ANDROGEL 1 % (50 MG) TD GLPK C-III Moderate dependence Yes 112505 ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) TRANSDERMAL GLPK C-III Moderate dependence Yes 112504 ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) TRANSDERMAL GLPK C-III Moderate dependence Yes 36354 ANDROGEL 12.5 MG/ACTUATION TD GLPM C-III Moderate dependence Yes 104139 ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) TRANSDERMAL GLPM C-III Moderate dependence Yes 18493 ANDROID 10 MG ORAL CAP C-III Moderate dependence Yes 41373 ANDROSTENEDIONE (BULK) 98.5 % MISC POWD C-III Moderate dependence Yes 36220 ANDROXY 10 MG ORAL TAB C-III Moderate dependence Yes 64616 ARMODAFINIL 150 MG ORAL TAB C-IV Limited Dependence Yes 64618 ARMODAFINIL 250 MG ORAL TAB C-IV Limited Dependence Yes 64617 ARMODAFINIL 50 MG ORAL TAB C-IV Limited Dependence Yes 11000 ASA-CAFF-BUTALBITAL-CODEINE 325-40-50-30 MG ORAL CAP C-III Moderate dependence Yes 20899 ASCOMP W/CODEINE 325-40-50-30 MG ORAL CAP C-III Moderate dependence Yes 14553 ASPIRIN-CAFFEINE-BUTALBITAL 325-40-50 MG ORAL CAP C-III Moderate dependence Yes 14378 ASPIRIN-CAFFEINE-BUTALBITAL 325-40-50 MG ORAL TAB C-III Moderate dependence Yes 353 ASTRAMORPH 0.5 MG/ML INJ SOLN C-II High abuse potential Yes 10946 ASTRAMORPH 1 MG/ML INJ SOLN C-II High abuse potential Yes 17667 ATIVAN 0.5 MG ORAL TAB C-IV Limited Dependence Yes 4253 ATIVAN 1 MG ORAL TAB C-IV Limited Dependence Yes 6063 ATIVAN 2 MG ORAL TAB C-IV Limited Dependence Yes 19995 ATIVAN 2 MG/ML INJ SOLN C-IV Limited Dependence Yes 4165 ATIVAN 4 MG/ML INJ SOLN C-IV Limited Dependence Yes 106216 ATIVAN1MG/BENADRYL25MG/HALDOL2.5MG (ABH) PER 10ML SUSPENSION C-IV Limited Dependence Yes 21565 AVINZA 120 MG ORAL CM24 C-II High abuse potential Yes 21562 AVINZA 30 MG ORAL CM24 C-II High abuse potential Yes 64697 AVINZA 45 MG ORAL CM24 C-II High abuse potential Yes 21563 AVINZA 60 MG ORAL CM24 C-II High abuse potential Yes 64698 AVINZA 75 MG ORAL CM24 C-II High abuse potential Yes 21564 AVINZA 90 MG ORAL CM24 C-II High abuse potential Yes 103771 AXIRON 30 MG/1.5 ML /ACTUATION TRANSDERMAL SLPM C-III Moderate dependence Yes 11862 BELLADONNA ALKALOIDS-OPIUM 16.2-30 MG RECTAL
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Orange Book Cumulative Supplement 6 June 2011

    Orange Book Cumulative Supplement 6 June 2011

    CUMULATIVE SUPPLEMENT 6 June 2011 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 31st EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2011 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 31st EDITION Cumulative Supplement 6 June 2011 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Cumulative Supplement Content....................................................................................................... iv 1.3 Applicant Name Changes................................................................................................................... v 1.4 Levothyroxine Sodium........................................................................................................................ v 1.5 Availability of the Edition ................................................................................................................... vi 1.6 Report of Counts for the Prescription Drug Product List .................................................................. vii 1.7 Cumulative Supplement Legend ......................................................................................................viii
  • Brain Imaging

    Brain Imaging

    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
  • Radiotracers for SPECT Imaging: Current Scenario and Future Prospects

    Radiotracers for SPECT Imaging: Current Scenario and Future Prospects

    Radiochim. Acta 100, 95–107 (2012) / DOI 10.1524/ract.2011.1891 © by Oldenbourg Wissenschaftsverlag, München Radiotracers for SPECT imaging: current scenario and future prospects By S. Adak1,∗, R. Bhalla2, K. K. Vijaya Raj1, S. Mandal1, R. Pickett2 andS.K.Luthra2 1 GE Healthcare Medical Diagnostics, John F Welch Technology Center, Bangalore, India 560066 2 GE Healthcare Medical Diagnostics, The Grove Centre, White Lion Road, Amersham, HP7 9LL, UK (Received October 4, 2010; accepted in final form July 18, 2011) Nuclear medicine / 99m-Technetium / 123-Iodine / ton emission computed tomography (SPECT or less com- Oncological imaging / Neurological imaging / monly known as SPET) and positron emission tomogra- Cardiovascular imaging phy (PET). Both techniques use radiolabeled molecules to probe molecular processes that can be visualized, quanti- fied and tracked over time, thus allowing the discrimination Summary. Single photon emission computed tomography of healthy from diseased tissue with a high degree of con- (SPECT) has been the cornerstone of nuclear medicine and today fidence. The imaging agents use target-specific biological it is widely used to detect molecular changes in cardiovascular, processes associated with the disease being assessed both at neurological and oncological diseases. While SPECT has been the cellular and subcellular levels within living organisms. available since the 1980s, advances in instrumentation hardware, The impact of molecular imaging has been on greater under- software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper. standing of integrative biology, earlier detection and charac- The biggest change in the last decade has been the fusion terization of disease, and evaluation of treatment in human of CT with SPECT, which has improved attenuation correction subjects [1–3].
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy

    Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy

    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
  • Nuclear Pharmacy Quick Sample

    Nuclear Pharmacy Quick Sample

    12614-01_CH01-rev3.qxd 10/25/11 10:56 AM Page 1 CHAPTER 1 Radioisotopes Distribution for Not 1 12614-01_CH01-rev3.qxd 10/25/1110:56AMPage2 2 N TABLE 1-1 Radiopharmaceuticals Used in Nuclear Medicine UCLEAR Chemical Form and Typical Dosage P Distribution a b HARMACY Radionuclide Dosage Form Use (Adult ) Route Carbon C 11 Carbon monoxide Cardiac: Blood volume measurement 60–100 mCi Inhalation Carbon C 11 Flumazenil injection Brain: Benzodiazepine receptor imaging 20–30 mCi IV Q UICK Carbon C 11 Methionine injection Neoplastic disease evaluation in brain 10–20 mCi IV R Carbon C 11 forRaclopride injection Brain: Dopamine D2 receptor imaging 10–15 mCi IV EFERENCE Carbon C 11 Sodium acetate injection Cardiac: Marker of oxidative metabolism 12–40 mCi IV Carbon C 14 Urea Diagnosis of Helicobacter pylori infection 1 µCi PO Chromium Cr 51 Sodium chromate injection Labeling red blood cells (RBCs) for mea- 10–80 µCi IV suring RBC volume, survival, and splenic sequestration Cobalt Co 57 Cyanocobalamin capsules Diagnosis of pernicious anemia and 0.5 µCi PO Not defects of intestinal absorption Fluorine F 18 Fludeoxyglucose injection Glucose utilization in brain, cardiac, and 10–15 mCi IV neoplastic disease Fluorine F 18 Fluorodopa injection Dopamine neuronal decarboxylase activity 4–6 mCi IV in brain Fluorine F 18 Sodium fluoride injection Bone imaging 10 mCi IV Gallium Ga 67 Gallium citrate injection Hodgkin’s disease, lymphoma 8–10 mCi IV Acute inflammatory lesions 5 mCi IV Indium In 111 Capromab pendetide Metastatic imaging in patients with biopsy-
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

    Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
  • ALC Neuroprotection in Mitochondrial Dysfunction V2 Mar2013x

    ALC Neuroprotection in Mitochondrial Dysfunction V2 Mar2013x

    LÍDIA ALEXANDRA DOS SANTOS CUNHA ACETYL -L-CARNITINE NEUROPROTECTION IN MITOCHONDRIAL DYSFUNCTION Tese de Candidatura ao Grau de Doutor em Patologia e Genética Molecular, submetida ao Instituto de Ciências Biomédicas Abel Salazar Universidade do Porto Orientadora: Doutora Maria Teresa Burnay Summavielle Categoria: Investigador Auxiliar Afiliação: Instituto de Biologia Molecular e Celular DIRECTIVAS LEGAIS Nesta Tese foram apresentados os resultados contidos nos artigos publicados ou em vias de publicação seguidamente mencionados: Cunha L , Horvath I, Ferreira S, Lemos J, Costa P, Vieira D, Veres DS, Szigeti K, Summavielle T, Máthé D, Metello LF Preclinical imaging: an essential ally in biosciences and drug development (Submitted for publication) Cunha L , Bravo J, Fernandes S, Magalhães A, Costa P, Metello LF, Horvath I, Borges F, Szigeti K, Máthé D, Summavielle T Acetyl-L-Carnitine preconditioning in methamphetamine exposure leads to excessive glucose uptake impairing reference memory and deregulated mitochondrial membrane function (Submitted for publication) Summavielle T, Cunha L , Damiani D , Bravo J, Binienda Z, Koverech A , Virmani A (2011) Neuroprotective action of acetyl-L-carnitine on methamphetamine-induced dopamine release . American Journal of Neuroprotection and Neuroregeneration 3:1-7. Comunicações orais apresentadas em congressos internacionais: Cunha L , Bravo J, Gonçalves R, Rodrigues C, Rodrigues A, Metello LF, Summavielle T The role of mitochondria in acetyl-L-carnitine neuroprotective action European Association of Nuclear Medicine Annual Congress. October 2012. Birmingham, UK. Eur J Nucl Med Mol Imaging (2011) 38 (Suppl 2):S227 iii Apresentações sob a forma de poster em congressos internacionais: Cunha L , Bravo J, Costa P, Fernandes S, Oliveira M, Castro R, Metello LF, Summavielle T Acetyl-L-carnitine improves cell bioenergetics European Association of Nuclear Medicine Annual Congress.
  • Monoamine Reuptake Inhibitors in Parkinson's Disease

    Monoamine Reuptake Inhibitors in Parkinson's Disease

    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
  • Mechanisms of Radiopharmaceutical Localization

    Mechanisms of Radiopharmaceutical Localization

    .::VOLUME 16, LESSON 4::. Mechanisms of Radiopharmaceutical Localization Continuing Education for Nuclear Pharmacists And Nuclear Medicine Professionals By James A. Ponto, MS, RPh, BCNP Chief Nuclear Pharmacists, University of Iowa Hospitals and Clinics and Professor (Clinical), University of Iowa Hospitals and Clinics The University of New Mexico Health Sciences Center, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program No. 0039-000-12-164- H04-P 2.5 Contact Hours or .25 CEUs. Initial release date: 7/19/2012 -- Intentionally left blank -- Mechanisms of Radiopharmaceutical Localization By James A. Ponto, MS, RPh, BCNP Editor, CENP Jeffrey Norenberg, MS, PharmD, BCNP, FASHP, FAPhA UNM College of Pharmacy Editorial Board Stephen Dragotakes, RPh, BCNP, FAPhA Michael Mosley, RPh, BCNP Neil Petry, RPh, MS, BCNP, FAPhA James Ponto, MS, RPh, BCNP, FAPhA Tim Quinton, PharmD, BCNP, FAPhA S. Duann Vanderslice, RPh, BCNP, FAPhA John Yuen, PharmD, BCNP Advisory Board Dave Engstrom, PharmD, BCNP Vivian Loveless, PharmD, BCNP, FAPhA Brigette Nelson, MS, PharmD, BCNP Brantley Strickland, BCNP Susan Lardner, BCNP Christine Brown, BCNP Director, CENP Administrator, CE & Web Publisher Kristina Wittstrom, MS, RPh, BCNP, FAPhA Christina Muñoz, M.A. UNM College of Pharmacy UNM College of Pharmacy While the advice and information in this publication are believed to be true and accurate at the time of press, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, expressed or implied, with respect to the material contained herein.
  • Neurochemical Features of Rem Sleep Behaviour Disorder

    Neurochemical Features of Rem Sleep Behaviour Disorder

    Journal of Personalized Medicine Review Neurochemical Features of Rem Sleep Behaviour Disorder Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1, Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, C/Marroquina 14, 3 B, E28030 Madrid, Spain; [email protected] 2 UNEx, ARADyAL, Instituto de Salud Carlos III, University Institute of Molecular Pathology, E10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected] or [email protected]; Tel.: +34-636968395; Fax: +34-913280704 Abstract: Dopaminergic deficiency, shown by many studies using functional neuroimaging with Sin- gle Photon Emission Computerized Tomography (SPECT) and Positron Emission Tomography (PET), is the most consistent neurochemical feature of rapid eye movement (REM) sleep behaviour disorder (RBD) and, together with transcranial ultrasonography, and determination of alpha-synuclein in certain tissues, should be considered as a reliable marker for the phenoconversion of idiopathic RBD (iRBD) to a synucleopathy (Parkinson’s disease –PD- or Lewy body dementia -LBD). The possible role in the pathogenesis of RBD of other neurotransmitters such as noradrenaline, acetylcholine, and excitatory and inhibitory neurotransmitters; hormones such as melatonin, and proinflammatory factors have also been suggested by recent reports. In general, brain perfusion and brain glucose metabolism studies have shown patterns resembling partially those of PD and LBD. Finally, the results of structural and functional MRI suggest the presence of structural changes in deep gray matter nuclei, cortical gray matter atrophy, and alterations in the functional connectivity within the basal ganglia, the cortico-striatal, and the cortico-cortical networks, but they should be considered as preliminary.
  • Datscan™ (Ioflupane I 123 Injection) Patient Prep: Potential Drug Interference

    Datscan™ (Ioflupane I 123 Injection) Patient Prep: Potential Drug Interference

    GE Healthcare DaTscan™ (Ioflupane I 123 Injection) Patient Prep: Potential Drug Interference Drugs that bind to the dopamine transporter with high affinity may interfere with the DaTscan image. Whether discontinuation of these drugs prior to DaTscan administration may minimize the interference with a DaTscan image is unknown. The impact of dopamine agonists and antagonists on DaTscan imaging results has not been established. The benefits and risks of stopping a medication that may interfere with the reliability of the information in a DaTscan image is a medical consideration that should be made on an individual basis. The decision to withhold or stop any potentially interacting medication should be determined by the patient’s physician(s), in consultation with a pharmacist, after obtaining a thorough medication history. The information below is provided for your consideration when evaluating how to handle concomitant medications prior to administration of DaTscan for single-photon emission computed tomography (SPECT) imaging.1 The following drugs mat not interfere with ioflupane binding: • Cholinesterase inhibitors and neuroleptics • Anti-parkinsonian drugs (eg, L-dihydroxyphenylalanine, dopamine agonists, monoamine oxidase-B inhibitors, N-methyl-D-aspartate receptor blockers, amantadine, and catechol-O-methyltransferase inhibitors in standard dosages) • Selective serotonin reuptake inhibitors may increase binding to the DaT somewhat but should not interfere with visual interpretation Medication or drug that may interfere with ioflupane binding. 5 half-lives is approximately equal to: Consider stopping such medication for at least 5 half-lives1 Ephedrine, ketamine, isoflurane 1 day Cocaine, methylphenidate 2 days Methamphetamine, mazindol, modafinil 3 days Benztropine, fentanyl 5 days Amphetamine, Dexamphetamine 7 days Bupropion 8 days Phentermine, phencyclidine 14 days Reference: 1.